Keybanc Downgrades Cooper Companies to Sector Weight

Keybanc analyst Matthew Mishan downgrades Cooper Companies (NYSE:COO) from Overweight to Sector Weight.

Keybanc analyst Matthew Mishan downgrades Cooper Companies (NYSE:COO) from Overweight to Sector Weight.

Total
0
Shares
Related Posts
Read More

Akari Therapeutics Announced Updates On Progress In The Pre-clinical Development Program For Long-Acting PAS-Nomacopan As A Potential Treatment For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration

Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024. Composition of matter patent application filed on long-acting PAS-nomacopan versions, which, if granted,

AKTX

Read More

Travere Therapeutics Announces Late-Breaking Data From Phase 3 Studies Of Sparsentan In IgAN And FSGS Published In The Lancet And The NEJM Respectively And Presented At The American Society Of Nephrology Kidney Week 2023

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure, suggesting

TVTX